Biosimilar rollouts: practice, pitfalls and the importance of effective communication
- 14 September 2025
- journal article
- Published by BMJ in Practical Neurology
- Vol. 26 (2) , 104-105
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Diagnostic uncertainty in the era of biosimilar natalizumab—The case for harmonizing anti-JCV antibody testingMultiple Sclerosis Journal, 2025
- Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?Multiple Sclerosis Journal, 2025
- A comparison of JC virus assay performance provided with originator and biosimilar natalizumabMultiple Sclerosis Journal, 2025
- Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple SclerosisJAMA Neurology, 2025
- Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar NatalizumabBioDrugs, 2024
- Maximizing the success of biosimilar implementationNature Reviews Rheumatology, 2023
- Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendationsMultiple Sclerosis Journal, 2022
- Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic ReviewBioDrugs, 2021
- What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsBMC Medicine, 2015